Centers | ||
Presude Life Sciences | EU-OPENSCREEN | Therapeutic Accelerator Program (TAP) |
Presude Lifesciences is an integrated drug discovery and development services organization led by biopharma professionals with global experience. Read morePresude is a research driven company with expertise in medicinal chemistry, custom synthesis and... |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Test |
Partnerships |
Events |
Jobs |
Yale to Partner with Gilead to Further Cancer ResearchYale and Gilead have entered into a multi-year research collaboration to develop new treatments against cancer. Gilead will provide $40million in funding for research and other infrastructure support for the initial four years. The agreement can... View all Sanford-Burnham Partners with Johnson and Johnson to Identify New Treatments for Neurological DisordersSanford-Burnham Medical Institute and Janssen a unit of Johnson and Johnson have entered into research and development partnership to identify novel targets and develop drugs to treat Alzheimer's disease and psychiatric disorders. This multi year... View all Johnson & Johnson to Support Pain Research at Queensland UniversityJohnson & Johnson and Institute for Molecular Bioscience (IMB) at University of Queensland have entered into research agreement to develop peptides using IMB's novel assay to treat chronic pain. Johnson & Johnson and its affiliates will provide... View all |
No EVENTS for listing |
No Job Posts |


